Programmed cell death and lipid metabolism of macrophages in NAFLD DOI Creative Commons
Zhun Xiao, Minghao Liu,

Fangming Yang

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Jan. 18, 2023

Non-alcoholic fatty liver disease (NAFLD) has now become the leading chronic worldwide with lifestyle changes. This may lead to NAFLD becoming cause of end-stage in future. To date, there are still no effective therapeutic drugs for NAFLD. An in-depth exploration pathogenesis can help provide a basis new agents or strategies. As most important immune cells liver, macrophages play an role occurrence and development inflammation expected targets treatment. Programmed cell death (PCD) plays regulatory phenotypic transformation, is also certain connection between different types PCD. However, how PCD regulates macrophage polarization not been systematically elucidated. Based on lipid metabolic reprogramming polarization, alter phenotype by regulating metabolism. We reviewed effects changes their metabolism, as well relationship metabolism macrophages. Furthermore, interactions potential targeting explored.

Language: Английский

Ferroptosis, a new pathogenetic mechanism in cardiometabolic diseases and cancer: Is there a role for statin therapy? DOI
Amirhossein Sahebkar,

Zahra Foroutan,

Niki Katsiki

et al.

Metabolism, Journal Year: 2023, Volume and Issue: 146, P. 155659 - 155659

Published: July 11, 2023

Language: Английский

Citations

32
Natural products in non-alcoholic fatty liver disease (NAFLD): Novel lead discovery for drug development DOI Creative Commons
Lu Wang,

Yonghuan Yan,

Linfang Wu

et al.

Pharmacological Research, Journal Year: 2023, Volume and Issue: 196, P. 106925 - 106925

Published: Sept. 13, 2023

With changing lifestyles, non-alcoholic fatty liver disease (NAFLD) has become the most prevalent worldwide. A substantial increase in incidence, mortality, and associated burden of NAFLD-related advanced is expected. Currently, initial diagnosis NAFLD still based on ultrasound there no approved treatment method. Lipid-lowering drugs, vitamin supplementation, lifestyle improvement treatments are commonly used clinical practice. However, lipid-lowering drugs can produce poor patient compliance specific adverse effects. Therefore, exploration bio-diagnostic markers active lead compounds for development innovative urgently needed. More more studies have reported anti-NAFLD effects mechanisms natural products (NPs), which an important source new drug to treat due their high activity low side At present, berberine silymarin been by US FDA enter phase IV studies, demonstrating potential NPs against NAFLD. Studies found that regulation lipid metabolism, insulin resistance, oxidative stress, inflammation-related pathways may play roles process. continuous updating technical means scientific theories, in-depth research targets provide possibilities find drugs. As we know, FXR agonists, PPARα dual CCR2/5 inhibitors gradually coming stage Whether exert regulating these or some unknown remains be further studied. study reviewed targets. Some works discovery docking were also discussed. It hoped this review reference values non-invasive diagnostic clinic.

Language: Английский

Citations

29
Dietary and lifestyle oxidative balance scores are independently and jointly associated with nonalcoholic fatty liver disease: a 20 years nationally representative cross-sectional study DOI Creative Commons
Yuanbin Liu, Mingkai Chen

Frontiers in Nutrition, Journal Year: 2023, Volume and Issue: 10

Published: Oct. 18, 2023

Background Oxidative stress is an important contributor to the progression of nonalcoholic fatty liver disease (NAFLD), but whether dietary and lifestyle pro- antioxidants may have combined or independent effects on NAFLD, advanced fibrosis (AHF) remains unclear. We aimed elucidate relationship between a well-established oxidative balance score (OBS) NAFLD/AHF. Methods This was cross-sectional study. included adult participants with complete data from National Health Nutrition Examination Survey 1999–2018. Survey-weighted adjusted multivariate regression analyses were used examine association all OBS A combination restricted cubic splines, mediation analysis, stratified sensitivity analysis further these associations. Results 6,341 eligible prevalence NAFLD AHF 30.2 13.9%, respectively. In fully model, highest quartile OBS, associated 65, 55, 77% reduced risk respectively, compared reference population, However, not AHF. All nonlinearly had more pronounced for after exceeding 26, 21, 5 points, exert protective effect indirectly through inflammation, stress, glycolipid metabolism markers. Stratification demonstrate robustness our findings. Conclusion negatively risk. These

Language: Английский

Citations

24
Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches DOI Creative Commons
Seyedeh Kosar Mahmoudi,

Shadi Tarzemani,

Taha Aghajanzadeh

et al.

European journal of medical research, Journal Year: 2024, Volume and Issue: 29(1)

Published: March 20, 2024

Abstract Non-alcoholic fatty liver disease (NAFLD) is one of the leading causes chronic diseases, affecting more than one-quarter people worldwide. Hepatic steatosis can progress to severe forms NAFLD, including NASH and cirrhosis. It also may develop secondary diseases such as diabetes cardiovascular disease. Genetic environmental factors regulate NAFLD incidence progression, making it a complex The contribution various risk factors, type 2 diabetes, obesity, hyperlipidemia, diet, sedentary lifestyle, exacerbation injury highly understood. Nevertheless, underlying mechanisms genetic variations in occurrence or its deterioration still need be clarified. Hence, understanding susceptibility essential for controlling course current review discusses genetics’ role pathological pathways lipid glucose metabolism, insulin resistance, cellular stresses, immune responses. Additionally, explains components induction progression lean individuals. Finally, highlights utility knowledge precision medicine early diagnosis treatment patients.

Language: Английский

Citations

14
Resmetirom's approval: Highlighting the need for comprehensive approaches in NASH therapeutics DOI
Salah Abdalrazak Alshehade

Clinics and Research in Hepatology and Gastroenterology, Journal Year: 2024, Volume and Issue: 48(7), P. 102377 - 102377

Published: May 19, 2024

Language: Английский

Citations

13
Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies DOI Creative Commons
Xin Ding, Xu He,

Bulang Tang

et al.

Chinese Medicine, Journal Year: 2024, Volume and Issue: 19(1)

Published: Feb. 3, 2024

Abstract Traditional Chinese medicine (TCM) has been widely used for several centuries metabolic diseases, including non-alcoholic fatty liver disease (NAFLD). At present, NAFLD become the most prevalent form of chronic worldwide and can progress to steatohepatitis (NASH), cirrhosis, even hepatocellular carcinoma. However, there is still a lack effective treatment strategies in Western medicine. The development driven by multiple mechanisms, genetic factors, insulin resistance, lipotoxicity, mitochondrial dysfunction, endoplasmic reticulum stress, inflammation, gut microbiota dysbiosis, adipose tissue dysfunction. Currently, certain drugs, sensitizers, statins, vitamin E, ursodeoxycholic acid betaine, are proven be beneficial clinical NAFLD. Due its complex pathogenesis, personalized that integrates various mechanisms may provide better benefits patients with holistic view syndrome differentiation TCM have advantages treating NAFLD, which similar principles In TCM, primarily classified into five types based on experience. It located closely related spleen kidney functions. due multi-component characteristics traditional medicine, application considerably limited. this review, we summarize advances pathogenesis drawn from both perspectives. We highlight complementary should receive increased attention prevention

Language: Английский

Citations

12
Prognostic nutritional index (PNI) and risk of non-alcoholic fatty liver disease and advanced liver fibrosis in US adults: Evidence from NHANES 2017–2020 DOI Creative Commons
Ge Chen, Liqing Fan,

Ting Yang

et al.

Heliyon, Journal Year: 2024, Volume and Issue: 10(4), P. e25660 - e25660

Published: Feb. 1, 2024

ObjectiveThis study explored the potential association between Prognostic Nutritional Index (PNI) and incidence of non-alcoholic fatty liver disease (NAFLD) advanced fibrosis (AF) in adult population United States.MethodsInformation on 6409 participants ≥18 years old was downloaded from U.S. National Health Nutrition Examination Survey (NHANES) 2017 to 2020. Multivariate analysis combined with demographic factors assess relationships PNI, NAFLD, AF. A restricted cubic spline (RCS) used characterise nonlinear PNI NAFLD AF.ResultsPatients without had substantially lower mean values for parameters such as age, lymphocyte count, neutrophil neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte (PLR), systemic immune-inflammatory index (SII), total cholesterol, triglycerides, HbA1c, aspartate aminotransferase (AST), alanine (ALT) than patients NAFLD. Interestingly, non-NAFLD showed a pronounced increase serum albumin levels compared their counterparts. In subset AF, there were discernibly measures NLR, AST, ALT, γ-glutamyl transferase, body mass (BMI) It evident that those AF markedly elevated comparison AF-affected individuals. comprehensive multivariable framework, direct correlation observed (adjusted odds ratio[aOR] = 1.07, 95% confidence interval [CI]: 1.05–1.09; p < 0.001), whereas inversely correlated (aOR 0.92; CI: 0.88–0.96; 0.001). Within RCS model, swift ascendancy noted relationship peaking at approximately 52. Conversely, non-linear inverse AF.ConclusionOur analytical results indicate are positively associated an increased risk but related For robust validation these observations, further research is required.

Language: Английский

Citations

12
Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease DOI Open Access
Manuel Soto‐Catalán, Lucas Opazo-Ríos,

Hernán Quiceno

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(5), P. 2961 - 2961

Published: March 4, 2024

Metabolic-dysfunction-associated steatotic liver disease (MASLD) is a prevalent clinical condition associated with elevated morbidity and mortality rates. Patients MASLD treated semaglutide, glucagon-like peptide-1 receptor agonist, demonstrate improvement in terms of damage. However, the mechanisms underlaying this beneficial effect are not yet fully elucidated. We investigated efficacy semaglutide halting progression using genetic mouse model diabesity. Leptin-receptor-deficient mice obesity diabetes (BKS db/db) were either untreated or administered for 11 weeks. Changes food water intake, body weight glycemia monitored throughout study. Body fat composition was assessed by dual-energy X-ray absorptiometry. Upon sacrifice, serum biochemical parameters, morphology, lipidomic profile liver-lipid-related pathways evaluated. The semaglutide-treated exhibited lower levels glycemia, weight, markers dysfunction total percentage mass compared to db/db without significant reduction intake. Histologically, reduced hepatic steatosis, hepatocellular ballooning intrahepatic triglycerides. Furthermore, treatment ameliorated expression de novo lipogenesis modified lipid increasing amount polyunsaturated fatty acids. administration leptin-receptor-deficient, hyperphagic diabetic resulted amelioration MASLD, likely independently daily caloric suggesting direct on through modulation profile.

Language: Английский

Citations

11
Efficacy of probiotics, prebiotics, and synbiotics on liver enzymes, lipid profiles, and inflammation in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials DOI Creative Commons

Youwen Pan,

Yafang Yang,

Jiale Wu

et al.

BMC Gastroenterology, Journal Year: 2024, Volume and Issue: 24(1)

Published: Aug. 22, 2024

There is a contradiction in the use of microbiota-therapies, including probiotics, prebiotics, and synbiotics, to improve condition patients with nonalcoholic fatty liver disease (NAFLD). The aim this review was evaluate effect microbiota-therapy on injury, inflammation, lipid levels individuals NAFLD. Using Pubmed, Embase, Cochrane Library, Web Science databases were searched for articles prebiotic, probiotic, or synbiotic treatment NAFLD up March 2024. Thirty-four studies involving 12,682 included. Meta-analysis indicated that supplementation significantly improved injury (hepatic fibrosis, SMD = -0.31; 95% CI: -0.53, -0.09; aspartate aminotransferase, -0.35; -0.55, -0.15; alanine -0.48; -0.71, -0.25; alkaline phosphatase, -0.81; -1.55, -0.08), profiles (triglycerides, -0.22; -0.43, -0.02), inflammatory factors (high-density lipoprotein, -0.47; -0.88, -0.06; tumour necrosis factor alpha, -0.86 -1.56, -0.56). Overall, had positive reducing enzymes, profiles, cytokines

Language: Английский

Citations

11
From MASH to HCC: the role of Gas6/TAM receptors DOI Creative Commons
Daria Apostolo, Luciana Louzada Ferreira,

Federica Vincenzi

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Jan. 17, 2024

Metabolic dysfunction-associated steatohepatitis (MASH) is the replacement term for what used to be called nonalcoholic (NASH). It characterized by inflammation and injury of liver in presence cardiometabolic risk factors may eventually result development hepatocellular carcinoma (HCC), most common form primary cancer. Several pathogenic mechanisms are involved transition from MASH HCC, encompassing metabolic injury, inflammation, immune dysregulation fibrosis. In this context, Gas6 (Growth Arrest-Specific 6) TAM (Tyro3, Axl, MerTK) receptors play important roles. The Gas6/TAM family modulation lipid metabolism, fibrosis, tumor progression metastasis, processes which an role pathophysiology acute chronic diseases. review, we discuss MASH-associated HCC potential involvement system disease progression. addition, since therapeutic strategies limited, also speculate regarding possible future treatments involving targeting or receptors.

Language: Английский

Citations

10